preview

Chronic Kidney Disease Case Study

Decent Essays

Final Question: In patients with non-dialysis-dependent (NDD) Chronic Kidney Disease (CKD) who have iron-deficiency anemia, how efficacious is intravenous (IV) ferric carboxymaltose in increasing hemoglobin levels and reducing treatment-related adverse events compared to IV iron sucrose?

P: patients with NDD-CKD who have iron-deficiency anemia
I: IV ferric carboxymaltose
C: IV iron sucrose
O: increase in hemoglobin levels and reduction in treatment-related adverse events

Evidence-based Answer: IV ferric carboxymaltose is more efficacious in increasing hemoglobin levels compared to IV iron sucrose. IV ferric carboxymaltose has a similar safety profile in terms of treatment-related adverse events compared to IV iron sucrose for treating patients with NDD-CKD who have iron-deficiency anemia. (Strength of Recommendation = A, based on consistent …show more content…

Randomized-control trials and cohort studies were identified by searching PubMED and some were provided by Vifor (financial supporter for the study). Studies were then rated on a scale of 1-5, with 5 equaling the lowest potential for bias. Studies with a score of two or greater were included in the study to limit bias. Patients in these studies were given either IV ferric carboxymaltose (n=2,348), IV iron sucrose (n=384), oral iron (n=832), or placebo (n=762). Results showed IV ferric carboxymaltose was better at attaining the target hemoglobin increase than comparators (NNT = 6.8; 95% CI: 5.3-9.7). Results also showed IV ferric carboxymaltose was better at reaching the target hemoglobin levels (NNT=5.9; 95% CI: 4.7-8.1). This meta-analysis was missing some hallmarks of a well-constructed meta-analysis (a stated question to answer, an explicitly-stated search strategy and evidence table). This qualifies as a large limitation to the

Get Access